Translate Bio Announces Results from Second Interim Data Analysis from Ongoing Phase 1/2 Clinical Trial of MRT5005 in Patients with Cystic Fibrosis (CF)
Solid Biosciences Reports Efficacy and Safety Data from the Ongoing IGNITE DMD Clinical Trial
bluebird bio announces that lentiviral vector BB305 is unlikely to be the cause of AML in clinical study of LentiGlobin for Sickle Cell Disease
Gene therapy for a subtype of eye disease approved in the Netherlands
From 2021, patients suffering from RPE65-associated retinal disease will be able to be treated in three UMCs of the Netherlands.
https://www.radboudumc.nl/nieuws/2020/gentherapie-voor-zeldzame-oogziekte-vergoed